This is a working overview of Research chemical, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-12. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Ibotenic acid acts as a potent agonist of the NMDA and group I (mGluR1 and mGluR5) and II (mGluR2 and mGluR3) metabotropic glutamate receptors. It is inactive at group III mGluRs. Ibotenic acid also acts as a weak agonist of the AMPA and kainate receptors. In vivo decarboxylation converts ibotenic acid into muscimol, which acts as a potent GABAA and GABAA-ρ receptor agonist. Unlike muscimol—the principal psychoactive constituent of Amanita muscaria that is understood to cause sedation and delirium—ibotenic acid's psychoactive effects are not known independent of its serving as a prodrug to muscimol, although some researchers have speculated that it would act as a stimulant. Ibotenic acid is an agonist of glutamate receptors, specifically at both the N-methyl-D-aspartate, or NMDA, and trans-ACPD receptor sites in multiple systems in the central nervous system. Ibotenic neurotoxicity can be enhanced by glycine and blocked by dizocilpine. Dizocilpine acts as an uncompetitive antagonist at NMDA receptors. Ibotenic acid toxicity comes from activation of the NMDA receptors. NMDA receptors are related to synaptic plasticity and work with metabotropic glutamate receptors to establish long term potentiation or LTP. The process of long term potentiation is believed to be related to the acquisition of information. The NMDA receptor functions properly by allowing Ca2+ ions to pass through after activation at the receptor site.
See also: Oral hypoglycemic agents. One of the sulfonylureas. (Diabeta; Glynase; Micronase; Euglucon) Glycemic index The effect of a food on blood glucose (sugar) levels over a period of time. Researchers have discovered that some kinds of foods raise blood glucose levels more quickly than other foods containing the same amount of carbohydrates, at least under laboratory conditions. Cooked carrots get glucose into the blood faster than pure glucose! In practice, foods are not eaten alone and the presence of other foods changes the measured results for the pure food. In addition, some foods do not have much carbohydrate even if they get it into the blood quickly. A better guide is glycemic density which combines the glycemic index with the amount of carbohydrate in the food. Glycogen A substance made from multiple glucose molecules. Sometimes called 'animal starch'. It is stored in liver and muscle cells and can be converted to glucose when needed. The glucose in liver glycogen is put back into the blood when required. That in muscle cells is not, as they lack the necessary enzymatic machinery to export glucose into the blood. Glycogenesis The process by which glycogen is formed from glucose. Controlled by insulin. See also: Glycogen. Glycosuria Having glucose (sugar) in the urine. This means that the renal threshold for glucose has been exceeded in the blood which is clear evidence of too high levels as the kidneys are ordinarily excellent at conserving glucose. For most kidneys, this is about 200 mg/dL.
When a DU penetrator reaches the interior of an armored vehicle, it catches fire, often igniting ammunition and fuel and possibly causing the vehicle to explode. DU is used by the U.S. Army in 120 mm or 105 mm cannons employed on the M1 Abrams tank. The DU content in various ammunition is 180 grams (6.3 oz) in 20 mm, 200 grams (7.1 oz) in 25 mm, 280 grams (9.9 oz) in 30 mm, 3.5 kilograms (7.7 lb) in 105 mm, and 4.5 kilograms (9.9 lb) in 120 mm penetrators. DU was used during the mid-1990s in the U.S. to make hand grenades, and land mines, but those applications have been discontinued, according to Alliant Techsystems. The US Navy used DU in its 20 mm Phalanx CIWS guns, but switched in the late 1990s to armor-piercing tungsten. Only the US and the UK have acknowledged using DU weapons. The Soviet Union and Russia have used DU weaponry since the 3BM-32 Vant, designed for the 125 mm tank cannons. In 2018, TASS reported that Russia was arming some of its T-80 models with 3BM60 Svinets-2 DU rounds. 782,414 DU rounds were fired during the 1991 war in Iraq, mostly by US forces. In a three-week period of conflict in Iraq during 2003, it was estimated that between 1,000 and 2,000 tonnes of depleted uranium munitions were used. More than 300,000 DU rounds were fired during the 2003 war, the vast majority by US troops.
In physics, the first law of thermodynamics is an expression of the conservation of total energy of a system. The increase of the energy of a system is equal to the sum of work done on the system and the heat added to that system:
Sources: en.wikipedia.org
=== Role in muscle regeneration === The first step to understanding the importance of macrophages in muscle repair, growth, and regeneration is that there are two "waves" of macrophages with the onset of damageable muscle use– subpopulations that do and do not directly have an influence on repairing muscle. The initial wave is a phagocytic population that comes along during periods of increased muscle use that are sufficient to cause muscle membrane lysis and membrane inflammation, which can enter and degrade the contents of injured muscle fibers. These early-invading, phagocytic macrophages reach their highest concentration about 24 hours following the onset of some form of muscle cell injury or reloading. Their concentration rapidly declines after 48 hours. The second group is the non-phagocytic types that are distributed near regenerative fibers. These peak between two and four days and remain elevated for several days while muscle tissue is rebuilding. The first subpopulation has no direct benefit to repairing muscle, while the second non-phagocytic group does. It is thought that macrophages release soluble substances that influence the proliferation, differentiation, growth, repair, and regeneration of muscle, but at this time the factor that is produced to mediate these effects is unknown. It is known that macrophages' involvement in promoting tissue repair is not muscle specific; they accumulate in numerous tissues during the healing process phase following injury.
== Role in gluconeogenesis == Fatty acids from lipids are commonly used as an energy source by vertebrates as fatty acids are degraded through beta oxidation into acetate molecules. This acetate, bound to the active thiol group of coenzyme A, enters the citric acid cycle (TCA cycle) where it is fully oxidized to carbon dioxide. This pathway thus allows cells to obtain energy from fat. To use acetate from fat for biosynthesis of carbohydrates, the glyoxylate cycle, whose initial reactions are identical to the TCA cycle, is used. Cell-wall containing organisms, such as plants, fungi, and bacteria, require very large amounts of carbohydrates during growth for the biosynthesis of complex structural polysaccharides, such as cellulose, glucans, and chitin. In these organisms, in the absence of available carbohydrates (for example, in certain microbial environments or during seed germination in plants), the glyoxylate cycle permits the synthesis of glucose from lipids via acetate generated in fatty acid β-oxidation. The glyoxylate cycle bypasses the steps in the citric acid cycle where carbon is lost in the form of CO2. The two initial steps of the glyoxylate cycle are identical to those in the citric acid cycle: acetate → citrate → isocitrate. In the next step, catalyzed by the first glyoxylate cycle enzyme, isocitrate lyase, isocitrate undergoes cleavage into succinate and glyoxylate (the latter gives the cycle its name). Glyoxylate condenses with acetyl-CoA (a step catalyzed by malate synthase), yielding malate.
== History == SOLAR began in 1975 as Soul Train Records, founded by Dick Griffey and Soul Train creator Don Cornelius. The first act they signed was an R&B vocal quartet they named The Soul Train Gang (Gerald Brown, Terry Brown, Judy Jones, Patricia Williamson, and later Denise Smith), who performed one of Soul Train's many themes, "Soul Train '75". Their first album was entitled Don Cornelius Presents The Soul Train Gang. In 1976, their second album, The Soul Train Gang, produced by Philly's Norman Harris, was released. The Gang broke up in 1977. That same year, singer/drummer Arnie Oliver, aka Ahaguna G. Sun, and singer/guitarist Werner "Bear" Schuchner formed Sunbear, a little-known soul/funk vocal duo that recorded in Los Angeles in 1977. Earth, Wind & Fire was a heavy influence on Sunbear, and there were also hints of Tower of Power and El Chicano in their sound. In 1977, Sunbear recorded its self-titled debut album for Don Cornelius and Dick Griffey's Soul Train Records, which evolved into Solar Records after Cornelius' departure in 1978. Sunbear broke up without ever recording a second album, and Oliver and Schuchner both went on to pursue other activities in the R&B world. Oliver became a member of Frankie Beverly's Maze, while Schuchner played guitar on albums by the Whispers, the Soul Train Gang, High Inergy, and others. In 1980, the Whispers recorded Sunbear's ballad "Fantasy" for their hit album Imagination. Griffey formed a collective called Shalamar, using a host of session singers to record "Uptown Festival," a disco-length medley of early Motown hits.
A retrospective study of patients with CRKp and CSKp infection asserted that the use of cephalosporins (a class of β-lactam antibiotics) used before invasive procedures was higher in patients with CRKp infection, suggesting that it is a risk factor. In a three-year study, the prevalence of CRE was shown to be proportional to the lengths of stays of the patients in those hospitals. Policies regarding contact precaution for patients infected or colonized by gram-negative pathogens were also observed in hospitals reporting decreases in CRE prevalence. One case study showed that patients with a compromised immune response are especially susceptible to both CRE exposure and infection. In one study, an elderly patient with acute lymphoblastic leukemia being treated in a long-term care facility contracted a CRE infection. Her age and condition, combined with her environment and regulation by a catheter and mechanical ventilation, all contributed to a higher susceptibility. Another major risk factor is being in a country with unregulated antibiotic distribution. In countries where antibiotics are over-the-counter and obtainable without a prescription, the incidence and prevalence of CRE infections were higher. One study from Japan found that 6.4% of healthy adults carried ESBL (mostly cefotaximase)-producing strains compared to 58.4% in Thailand, where antibiotics are available over the counter and without prescription. An Egyptian research group found that 63.3% of healthy adults were colonized.
== Personal life == Schumer dated professional wrestler Nic Nemeth, known by his ring name Dolph Ziggler, and comedian Anthony Jeselnik. She dated Ben Hanisch from 2015 to 2017. In early 2017, Schumer adopted a black dog named "Tati", after Tatiana Maslany. On February 13, 2018, Schumer married chef and farmer Chris Fischer in Malibu, California. In 2019, Schumer gave birth to their son via caesarean section due to her endometriosis. In September 2021, Schumer had her uterus removed to alleviate symptoms related to the condition. In February 2024, she announced that she had been diagnosed with Cushing's syndrome. Schumer announced her separation from Fischer on December 12, 2025. Schumer and Fischer divorced in September of 2026. In 2026, Schumer spoke publicly about her weight-loss journey, saying she had turned to the medication Mounjaro (tirzepatide) after previously discontinuing Ozempic and Wegovy because a GDF15 gene variant left her severely nauseated.
Sources: en.wikipedia.org
=== PE Applied Biosystems === In September 1995, Tony L. White from Baxter International Inc. became president and chief executive officer of Perkin-Elmer. In 1996 the company was reorganized into two separate operating divisions, Analytical Instruments and PE Applied Biosystems. The PE Applied Biosystems division accounted for half of Perkin-Elmer's total revenue, with net revenues up by 26%. In 1997, revenues reached almost US$1.3 billion, of which PE Applied Biosystems was US$653 million. The company acquired GenScope, Inc., and Linkage Genetics, Inc. The Linkage Genetics unit was combined with Zoogen to form PE AgGen, focused on genetic analysis services for plant and animal breeding. The PE Applied Biosystems division partnered with Hyseq, Inc., for work on the new DNA chip technology, and also worked with Tecan U.S., Inc., on combinatorial chemistry automation systems, and also with Molecular Informatics, Inc. on genetic data management and analysis automated systems.
Aleniglipron (development code GSBR-1290) is a small-molecule GLP-1 agonist developed by Structure Therapeutics. It is delivered orally and is in a Phase II trial as of 2023. In June 2024, Structure Therapeutics reported positive topline data from a Phase 2a obesity study in which GSBR-1290 demonstrated clinically meaningful and statistically significant placebo-adjusted mean weight loss and generally favorable safety and tolerability results.
==== 2013 resignation ==== In November 2013, Lad resigned from the Karnataka cabinet following allegations relating to illegal mining involving V. S. Lad & Sons, a company associated with his family. Contemporary reports stated that the company had been accused of illegal extraction and supply/export of iron ore. Lad said he resigned to avoid embarrassment to the Congress government and described his decision as a moral one. The resignation followed scrutiny of mining activity in the Ballari region and allegations concerning the classification of the company's mining lease. Reporting at the time also noted that the Karnataka Lokayukta had raised allegations concerning the company's mining activities.
Hahn remained modest and informal all his life. His disarming frankness, unfailing kindness, good common sense, and impish humour will be remembered by his many friends all over the world. The Royal Society in London wrote in an obituary:
== Clinical Applications == Since dermal fibroblasts play a critical role in wound healing, researchers are attempting to generate mature dermal fibroblasts to repair second and third degree burns. When the body sustains a third degree burn, the skin's dermal layer is completely destroyed by heat (and the all fibroblast cells within the wound site perish). Without fibroblasts, the wound site cannot regenerate extracellular matrix and epidermis skin cells cannot proliferate over the wound site. Therefore, without dermal fibroblasts the skin cannot properly recover from injury. Yet, by differentiating mesenchymal stem cells from other regions of the body and injecting them into the wound site, scientists can restore dermal fibroblasts to burned regions of the body. By restoring fibroblasts to the burned regions, the body can restore the ECM within the wound site and recover from the injury. As noted "The injured dermis is also repaired by the recruitment and proliferation of fibroblasts producing extracellular matrix and keratinocyte growth promoting factors." Similarly, FGF is being inserted into fibrin sealants to enhance the long term repair and sealing of tissue. FGF-1 has been experimentally shown to encourage the body’s own adhesive tissue to develop and effectively seal the wound (thereby stymieing infection and mitigating scar formation). Using FGF stimulate fibroblast activity is a more effective means of sealing tissue than current tissue sealants due to the robust nature of collagen which makes up connective tissue.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.